Member Info for HappyDays2U

Yep! That will be what the RNS says Pumpky, therefore a commitment they will need to RNS if not met.

Lots to look forward to.
Vatic TT completion in 2 days. Orders coming in and ABDX production line churning them out. On any day the EUA can be granted which will rocket the sales and the SP.

“the Company has successfully secured two contract service opportunities to date in 2022, one with an existing customer and one with a new European customer. One of these customers is in the ?eld of fertility testing, the other is in the ?eld of environmental monitoring, with both having commenced the process of SCALE-UP TO AUTOMATED MANUFACTURING.” (385,000 babies are born every day. Pregnancy testing is a very big market)

We also have a number of other non-COVID-19 opportunities in the pipeline in a range of different clinical areas and we are confident of converting 'a number of these' opportunities into signed contracts over the ‘coming months.’

Abingdon is in active discussions on additional contract services opportunities in the area of COVID-19 antigen testing speci?cally where the products are already in manufacture and a second manufacturer is required or there is a need to support a particular stage of the manufacturing process, for example in primary production where there may be a need to spray reagents on nitrocellulose and laminate to card format. A number of these discussions are advancing and we are ‘optimistic of commercial traction in due course.’

The Company is in the process of developing and launching an enhanced B2C e-commerce website, due for completion in Q2 2022 (April to June). The Directors believe that the direct-to-consumer lateral ?ow test market will grow signi?cantly and in its recent report, Future Market Insights forecasts the global market for self-testing kits will be worth US $11bn by 2030.

Our investment in automation means that we can ‘compete not only on scale and quantity of tests, but also on price’ whilst delivering a quality product to our customers, without the concerns of significant freight costs or timing delays associated with bringing product in from other areas of the world.

The Board is confident that the Company is well placed to take advantage of the expected growth in the lateral flow test market across the clinical, animal health, plant and environmental markets. Lateral flow tests are now much more widely understood and adopted by the general public and COVID-19 has highlighted the significant utility of these cost-effective rapid tests. The Board is encouraged by the pipeline of opportunities the Company is actively engaging with.

As a UK developer and manufacturer of lateral flow tests, the Company is uniquely placed to support its growing customer base as they focus on surety of supply and quality and the Board is confident that its redefined strategic plan will ultimately deliver value for shareholders.

Lots to look forward to.
Vatic TT completion in 2 days. Orders coming in and ABDX production line churning them out. On any day the EUA can be granted which will rocket the sales and the SP.

“the Company has successfully secured two contract service opportunities to date in 2022, one with an existing customer and one with a new European customer. One of these customers is in the ?eld of fertility testing, the other is in the ?eld of environmental monitoring, with both having commenced the process of SCALE-UP TO AUTOMATED MANUFACTURING.” (385,000 babies are born every day. Pregnancy testing is a very big market)

We also have a number of other non-COVID-19 opportunities in the pipeline in a range of different clinical areas and we are confident of converting 'a number of these' opportunities into signed contracts over the ‘coming months.’

Abingdon is in active discussions on additional contract services opportunities in the area of COVID-19 antigen testing speci?cally where the products are already in manufacture and a second manufacturer is required or there is a need to support a particular stage of the manufacturing process, for example in primary production where there may be a need to spray reagents on nitrocellulose and laminate to card format. A number of these discussions are advancing and we are ‘optimistic of commercial traction in due course.’

The Company is in the process of developing and launching an enhanced B2C e-commerce website, due for completion in Q2 2022 (April to June). The Directors believe that the direct-to-consumer lateral ?ow test market will grow signi?cantly and in its recent report, Future Market Insights forecasts the global market for self-testing kits will be worth US $11bn by 2030.

Our investment in automation means that we can ‘compete not only on scale and quantity of tests, but also on price’ whilst delivering a quality product to our customers, without the concerns of significant freight costs or timing delays associated with bringing product in from other areas of the world.

The Board is confident that the Company is well placed to take advantage of the expected growth in the lateral flow test market across the clinical, animal health, plant and environmental markets. Lateral flow tests are now much more widely understood and adopted by the general public and COVID-19 has highlighted the significant utility of these cost-effective rapid tests. The Board is encouraged by the pipeline of opportunities the Company is actively engaging with.

As a UK developer and manufacturer of lateral flow tests, the Company is uniquely placed to support its growing customer base as they focus on surety of supply and quality and the Board is confident that its redefined strategic plan will ultimately deliver value for shareholders.

Well it amazes me that after a couple of years of billions of LFT being used the whole world over some people think LFT's don't have a future???
ABDX is no start up, they have been doing this for 14 years, have all the suppliers in place and now all the equipment to produce in mass lined up and ready to go!
Very little competition within Europe. They are going to be very big indeed. Once at full capacity (matter of time and not all that much of it IMO) they will have turnover and profit in the 100's millions....12p a share! :)

For £15million you get a company with two factories that can make up to 150million tests a year. One product in FDA EUA lined up to produce in mass next week. In a growing sector, with growing pipeline of work. 124 employees, £9 million owed and likely to be paid in May.....what a bargain!

Yes I was hoping for Vatic pre order numbers, maybe we will get this next week once first batches have been delivered. For now we will need to settle for Firm orders.
"Vatic has placed firm purchase orders for the manufacture of Know-Now™ Tests"
It will explan all the Production personnel positions ABDX have been advertising for months. I'm expecting pre orders are significant and now they have a product to sell Vatic PR and sales team will be in full flow!

Lol, you know it's good news when the 1 post wonders come out to play.
Tide turned, lots of good news to look forward to over the coming months.

Wow! Lots and lots to digest there will read it all again. Well pleased with the partnership with Deepverge, I'm an investor with them also and they are going to be very big!
No unexpected bad news but lots of new good news....Happy days!

There will be lots to digest I’m sure, but the most likely headline part will be the Vatic pre-orders. If this is a large number, the SP is likely to fly. Medium numbers go up a bit, low possibly fall a bit.
The BA.2 wave is about to get going in the States so pressure on the FDA to get more tests on the market will be high. I’m therefore hopeful that Vatic will get the EUA in the not-too-distant future. If they can sell a large number before even having a EUA it will show the sort of numbers they will likely shift once they do have it (something that could come on any day) so we could see a lot of excitement over this.

Yes exactly. For a big drop we would need a left field bad thrown in. The last RNS basically cleared the air. We know they had a shocking H2 last year (£1.7 million). Yes maybe a delay in Vatic TT (unlikely in my view) but what else bad could they tell us that we don’t already know?
On the other hand…. Maybe a nice surprise with Vatic pre-order numbers, maybe news on developments with the companies they were in discussions with over outsourcing manufacturing. Maybe news that the government have committed to a date to pay their bill?.... who knows, maybe all fairly bog standard but I’m confident there is a better chance of right field good news we didn’t know being dropped in than left filed bad that we don’t already know.

Loskins, very interesting. I believe we are BioSUREs exclusive manufacturer so if this test belongs to them then ABDX will be manufacturing it....maybe news on this tomorrow then?

As I was saying last week. it’s a time to decide for yourselves what is good and what is not good news.
This needs to be decided in conjunction with what ABDX is currently Mcap valued of £13million.
It’s like trip adviser reviews, you know the ones where someone rips a £40 a night hotel room apart because there was a bit of dust above a doorframe. If you are staying in a £2000 a night room fair enough, but you can’t expect the same standards for 40 quid!
In market terms ABDX is a small firm. Priced lower than most start-ups with 3 or 4 employees. If these other firms suddenly announced contracts worth millions you can bet your bottom dollar their SP’s will double or more.
ABDX is a big (for AIM) firm but is now priced as a small one so results should be judged as a small firm. If the results suggest the bad patch is maybe over and things are now moving in the right direction, then this is all I need.
I’m expecting tomorrow will confirm the manufacturing team are now in production mode with the Vatic test and ready to up scale to meet demand = very good news.
Management expect turnover to be higher than the 6 months previous = good news
Whatever they say, I think there are a lot of people who sold out at a loss and will be gutted to see this rise and many who want in but haven’t done so yet, so will also hate to see a good rise. Thus, people will say the news is bad whatever it is. E.g. we know there will be some cash burn which practically guarantees a basher or two saying ‘placement risk within months SP at 4p bluur’. Just remember per the last RNS they have plans to mitigate these things if needed.
This is why I think you should always make up your own mind before the news, what do You think equals progress and not wait for others to sway your mind for you.

LP, I'm not sure what you mean. There is an announcement tomorrow. Its a full trading update so will include the details of the Vatic TT and any other current trading/prospects etc.
It all depends on what people class as good or not so good but equal chance of each. With a Mcap as low as ABDX who have money in the bank and money owed to them (added together higher than the Mcap) I would say it can't go a great deal lower.

Shanghai in lockdown just a province below is Fujian which is where nearly all of the test that currently feed the UK market are made.
So Boris, if your Chinese suppliers are all at home and you need millions of tests quickly what ya gonna do?

Or and BTW the US just recently put a public health warning out against your favourite tests.

https://www.fda.gov/medical-devices/safety-communications/do-not-use-certain-acon-flowflex-covid-19-tests-fda-safety-communication

Get home made test capabilities in place a pay your fricking bill ASAP!

Well big week next week then.
Keep in mind the last TT competed (in a now selling way,so not AVCT) was BioSURE and it sent the SP into the 80's......just saying :)

I know many may see me as over positive, but I mostly do this to counterbalance the many over the top negative people. There are always two sides to a coin.
I don’t want to build any over optimism. Personally, I think the 600,000 vatic pre-orders will be in or around the same, maybe a bit less, maybe a bit more. However, we could be pleasantly surprised?
For a company with an Mcap of £13million. Owed £9million which is expected to be paid within the next 10 weeks or so, money in the bank and…. Lets say producing 1million test for Vatic with more orders expected….. one would expect the SP to rocket from these very low levels.

Good to see some cool heads on here when many around them are losing theirs.
Tuesday, what will be will be. As I said earlier there will be stuff to feed the trolls (cash burn and TO compared to last year) so we can all expect the doom busters to appear but I’m confident there will be many positives as well. Everyone should read the RNS at least twice and make their own minds up before coming on here to see what others think.
One big positive is Vatic TT (trusting it is complete) brings the backdrop of big orders at any time. Once they have the FDA EUA that is likely to become a very big order indeed. Remember Vatic goal is for ABDX to be making 100 million tests for them a year. Get to that and ABDX SP will be in the £s! From this moment onwards those sort of orders and news could hit at any point.

JJ,
Fair questions and points and you are asking them in a respectful way so all fair play.
TT work for ABDX is definitely chargeable. They will pay their scientists e.g £20 an hour but charge clients e.g £40 an hour for their services. Clients need manufacturers and they will not take on all the risk to get a test ready for mass manufacturing on their own. Per the last RNS this is an area ‘Contract Service’ ABDX will be focusing on.
I take your point the Appel / Sony is not the best comparison, but I stick to my guns that if something is good it will sell.
Vatic has two massive selling points, Mutation proof (can stock up with piece of mind) and saliva only. Think the very elderly, sick and children with special needs etc. stick something right up their nose or pop a cotton bud in their mouth. These things will sell I’m sure.

As far as the price drop goes. Look at the volume its low. No one knows anything its just the MM's taking advantage of human emotions to encourage trade.
Whatever price the SP is on the results is what ABDX needs to be judged on. £100 million company turning over £2 million (%2) very bad. A £10 million one turning over £2million in 6 months (20%) is good.

JJ
I hear your point but if you apply the same logic to everything then we would all have next to no consumer choice. Apple would probably not be in existence as clearly everyone will continue buying Sony etc..
I work for a large firm, and we are constantly changing suppliers as I’m sure all do. It doesn’t matter when you come to market. If you have a good product it will sell.

Maybe a time to discuss and think about what to expect and hope for with the current trading update (Tuesday).
There are two ways to look at it. Compare the Jan to June numbers to what they turned over in the same period last year, this will be considerably lower I’m sure. Or compare it to what they turned over in the 6 months previous (£1.7 million). For me, if the next 6 months show an improvement on the last, then it means the company is going in the right direction and I will be happy with that.
There will be cash burn (I’m sure the trolls will jump all over that) but this is going into new products which are due to be in production before the end of the year so, for me again, as long as this is not alarming its ok with me.
Vatic TT and pre order numbers. I’m fairly confident that the pre orders even in low numbers will bring in a large chunk if not surpass the previous 6 months TO. However what Vatic bring is a lot of hope…but more than just hope. The TT is the difficult part, once done ABDX can up, or down scale as required. At any moment, on any day Vatic could strike a deal with a big supplier, government, organisation, NHS etc for e.g 5 million tests and the next day ABDX can be ramping up that order. I feel, it’s a matter of time before that test with all its plus points brings in some significant orders.
Covid is here to stay, there are 16,000 people in hospital with it at the moment. The last 2 years have caused a massive backlog in all other care as a result and its always going to be a massive uphill battle to tackle that while you have so many beds taken up with covid, and a large percentage of your doctors and nurses are giving people vaccinees.
We need a lot more Doctors and nurses.
A small army of people constantly vaccinating people.
And /or ways to only vaccinate people that need one and do more to stop people getting covid in the first place therefore keeping them out of hospital with it.
Testing is the only way to keep a lid of Covid and the costs to the public purse and society.
I do also thing Covid has made the average person more hypochondriacy. Don’t feel right, is it covid, is it flu, is it something else? I am a true believer this is the start of common practise for many to head to the internet, buy some tests and find out. I’m sure this will get government encouragement as that’s 50% of the GP waiting room no longer there.